
AeroVironment fell 64.0% from $280.95 to $101.11, behind the S&P 500's +10.6%. Its worst day was Mar 2 (−17.4%), and its low came Nov 18 at $101.11.
Nov 18, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $0.44 missed the $0.81 estimate on $472.5M revenue (est. $470.3M); FY revenue guidance of $1.9B–$2.0B against the $2.0B consensus.
−12.9% · S&P 500 +0.7%
Story events cover the past 12 months · Times ET
AeroVironment shares rose 16.1%, while the S&P 500 rose 0.7%.
+16.1% · S&P 500 +0.7%
AeroVironment closed at its highest level of the year, 39.8% above where the year started.
+3.8% · S&P 500 −0.1%
Raymond James moved AeroVironment from Strong Buy to Underperform; shares fell 17.4%.
−17.4%, the year's worst day, on 13M shares, the year's heaviest volume · S&P 500 +0.1%
EPS of $0.64 missed the $0.69 estimate on $408.0M revenue (est. $474.6M); FY revenue guidance of $1.9B–$1.9B against the $2.0B consensus.
−6.2% · S&P 500 −0.1%
AV and AFRL researchers will develop advanced ceramics, composites, and modeling techniques for extreme aerospace environmentsAeroVironment, Inc.
+18.3% · S&P 500 +0.6%
EPS of $1.84 beat the $1.48 estimate on $641.6M revenue (est. $559.9M); FY revenue guidance of $2.1B–$2.2B against the $2.2B consensus.
+18.8%, the year's best day · S&P 500 +0.8%
EPS of $0.59 beat the $0.24 estimate on $480.5M revenue (est. $458.5M); FY revenue guidance of $2.1B–$2.2B against the $2.2B consensus.
+4.4% · S&P 500 −0.6%
AeroVironment shares rose 12.6%, while the S&P 500 rose 2.4%.
+12.6% · S&P 500 +2.4%
Where it ended: a close of $101.11 on Nov 18, 2026. Up next: Q2 2027 earnings on Dec 8, 2026 (EPS est. $0.43, revenue est. $509.3M).
Nothing in the past 12 months.
All AVAV dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for AVAV and SPY from Benzinga historical bars. Not investment advice.